Details of Disease

General Information of Disease (ID: DISZTEK1)

Disease Name	Proliferative vitreoretinopathy
Disease Class	9B78: Vitreoretinopathy
Definition	Vitreoretinal membrane shrinkage or contraction secondary to the proliferation of primarily retinal pigment epithelial cells and glial cells, particularly fibrous astrocytes, followed by membrane formation. The formation of fibrillar collagen and cellular proliferation appear to be the basis for the contractile properties of the epiretinal and vitreous membranes.
Disease Hierarchy	DISB4B0F: Retinopathy DISZTEK1: Proliferative vitreoretinopathy
ICD Code	ICD-11 ICD-11: 9B78.2
Disease Identifiers	MONDO ID MONDO_0700115 MESH ID D018630 UMLS CUI C0242852 OMIM ID 193235 MedGen ID 66167 SNOMED CT ID 232016005

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 1 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Methotrexate	DM2TEOL	Approved	Small molecular drug	[1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 7 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
GP1BA	TTVB0Q9	Limited	Biomarker	[2]
IGFBP6	TTLAYV8	Limited	Altered Expression	[3]
AMD1	TTBFROQ	moderate	Biomarker	[4]
LTA	TTP73TM	Strong	Genetic Variation	[5]
SMN1	TT8QL6X	Strong	Altered Expression	[6]
TGFB2	TTI0KH6	Strong	Biomarker	[7]
LRP5	TT7VMG4	Definitive	Biomarker	[8]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 DTT(s)

This Disease Is Related to 17 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CAPN5	OTQ8QM7K	Limited	Biomarker	[9]
CRX	OTH435SV	Limited	Biomarker	[10]
DMBX1	OT43YF6N	Limited	Biomarker	[10]
EDA	OTAKS5WS	Limited	Altered Expression	[11]
EPRS1	OTXK0FLB	Limited	Biomarker	[12]
FBL	OTRODIE5	Limited	Genetic Variation	[13]
FMOD	OT9EJ5H8	Limited	Biomarker	[14]
MAP1B	OTVXW089	Limited	Altered Expression	[15]
OTX1	OTRGSGH9	Limited	Altered Expression	[10]
OTX2	OTTV05B1	Limited	Biomarker	[10]
TP53BP2	OTOWJ2Y4	Limited	Altered Expression	[16]
EMP2	OTPS2H0L	moderate	Altered Expression	[17]
PVR	OT3N91T7	Strong	Biomarker	[18]
RPE	OT0XT3JU	Strong	Biomarker	[19]
SMN2	OT54RLO1	Strong	Altered Expression	[6]
TCHP	OTVDMHSY	Strong	Biomarker	[20]
TTC36	OT90ZLHE	Strong	Biomarker	[21]
------------------------------------------------------------------------------------


⏷ Show the Full List of 17 DOT(s)

References

1	ClinicalTrials.gov (NCT04136366) The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy. U.S. National Institutes of Health.
2	A novel lipid prodrug strategy for sustained delivery of hexadecyloxypropyl 9-[2-(phosphonomethoxy)ethyl]guanine (HDP-PMEG) on unwanted ocular proliferation.Drug Deliv. 2017 Nov;24(1):1703-1712. doi: 10.1080/10717544.2017.1399303.
3	Expression of IGFBP? in proliferative vitreoretinopathy rat models and its effects on retinal pigment epithelialJ cells.Mol Med Rep. 2014 Jan;9(1):33-8. doi: 10.3892/mmr.2013.1794. Epub 2013 Nov 12.
4	Regulation of ADAM10 and ADAM17 by Sorafenib Inhibits Epithelial-to-Mesenchymal Transition in Epstein-Barr Virus-Infected Retinal Pigment Epithelial Cells.Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5162-73. doi: 10.1167/iovs.14-16058.
5	Characterisation of the inflammatory cytokine and growth factor profile in a rabbit model of proliferative vitreoretinopathy.Sci Rep. 2019 Oct 28;9(1):15419. doi: 10.1038/s41598-019-51633-8.
6	Safety, pharmacokinetics, and prevention effect of intraocular crocetin in proliferative vitreoretinopathy.Biomed Pharmacother. 2019 Jan;109:1211-1220. doi: 10.1016/j.biopha.2018.10.193. Epub 2018 Nov 7.
7	Blockade of MDM2 with inactive Cas9 prevents epithelial to mesenchymal transition in retinal pigment epithelial cells.Lab Invest. 2019 Dec;99(12):1874-1886. doi: 10.1038/s41374-019-0307-9. Epub 2019 Aug 22.
8	A model for familial exudative vitreoretinopathy caused by LPR5 mutations.Hum Mol Genet. 2008 Jun 1;17(11):1605-12. doi: 10.1093/hmg/ddn047. Epub 2008 Feb 9.
9	Proteomic insight into the pathogenesis of CAPN5-vitreoretinopathy.Sci Rep. 2019 May 20;9(1):7608. doi: 10.1038/s41598-019-44031-7.
10	Expression of VEGF-A, Otx homeobox and p53 family genes in proliferative vitreoretinopathy.Mediators Inflamm. 2013;2013:857380. doi: 10.1155/2013/857380. Epub 2013 Oct 21.
11	Regulation of fibronectin-EDA through CTGF domain-specific interactions with TGF2 and its receptor TGFRII.Invest Ophthalmol Vis Sci. 2011 Jul 7;52(8):5068-78. doi: 10.1167/iovs.11-7191.
12	OUTCOMES OF REPEAT PARS PLANA VITRECTOMY AFTER FAILED SURGERY FOR PROLIFERATIVE VITREORETINOPATHY.Retina. 2018 Sep;38 Suppl 1:S49-S59. doi: 10.1097/IAE.0000000000002000.
13	Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.World J Gastroenterol. 2015 Nov 21;21(43):12421-9. doi: 10.3748/wjg.v21.i43.12421.
14	Knockdown of Fibromodulin Inhibits Proliferation and Migration of RPE Cell via the VEGFR2-AKT Pathway.J Ophthalmol. 2018 Sep 12;2018:5708537. doi: 10.1155/2018/5708537. eCollection 2018.
15	Expression and upregulation of microtubule-associated protein 1B in cultured retinal pigment epithelial cells.Invest Ophthalmol Vis Sci. 1997 Dec;38(13):2852-6.
16	Small Interfering RNA Targeted to ASPP2 Promotes Progression of Experimental Proliferative Vitreoretinopathy.Mediators Inflamm. 2016;2016:7920631. doi: 10.1155/2016/7920631. Epub 2016 Jun 9.
17	Epithelial Membrane Protein-2 in Human Proliferative Vitreoretinopathy and Epiretinal Membranes.Invest Ophthalmol Vis Sci. 2016 Jun 1;57(7):3112-7. doi: 10.1167/iovs.15-17791.
18	Comparison of Chemokine CXCL-1 and Interleukin-6 Concentrations in the Subretinal Fluid and Vitreous in Rhegmatogenous Retinal Detachment.Ocul Immunol Inflamm. 2021 Feb 17;29(2):355-361. doi: 10.1080/09273948.2019.1672197. Epub 2019 Oct 29.
19	Substance P prevents development of proliferative vitreoretinopathy in mice by modulating TNF-.Mol Vis. 2017 Dec 13;23:933-943. eCollection 2017.
20	Phosphoinositide 3-kinase inactivation prevents vitreous-induced activation of AKT/MDM2/p53 and migration of retinal pigment epithelial cells.J Biol Chem. 2019 Oct 18;294(42):15408-15417. doi: 10.1074/jbc.RA119.010130. Epub 2019 Aug 29.
21	HBP21: a novel member of TPR motif family, as a potential chaperone of heat shock protein 70 in proliferative vitreoretinopathy (PVR) and breast cancer.Mol Biotechnol. 2008 Nov;40(3):231-40. doi: 10.1007/s12033-008-9080-5. Epub 2008 Jun 29.